Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Sinem Namdaroğlu; Şerife Solmaz Medeni; Tuğba Çetintepe; Ozan Barış Namdaroğlu; Oktay Bilgir

Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Year 2017, Volume: 10 Issue: 1, 67 - 72, 01.04.2017

Sinem Namdaroğlu Şerife Solmaz Medeni Tuğba Çetintepe Ozan Barış Namdaroğlu Oktay Bilgir

Abstract

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder characterized by recurrent arterial or venous thrombosis, fetal loss, thrombocytopenia, neurological symptoms and presence of serum antiphospholipid antibodies (AFA). In this report,we present a young male patient with thrombocytopenia who was refractory to steroids, intravenous immunoglobulin and splenectomy but had complete response to eltrombopag treatment, FV Leiden heterozygous mutant positive, also had a history of sinüs thrombosis taking oral anticoagulant treatment has been diagnosed primary APS. Eltrombopag treatment primary antiphospholipid syndrome patient associated with refractory thrombocytopenia.

Keywords

Eltrombopag, Primary antiphospholipid syndrome, Thrombocytopenia, Factor V Leiden

Refrakter trombositopeni ile seyreden Faktör V Leiden mutasyonu olan primer antifosfolipid sendromlu olguda eltrombopag deneyimi

Year 2017, Volume: 10 Issue: 1, 67 - 72, 01.04.2017

Sinem Namdaroğlu Şerife Solmaz Medeni Tuğba Çetintepe Ozan Barış Namdaroğlu Oktay Bilgir

Abstract

Antifosfolipid antikor sendromu (AFS), tekrarlayan arteriyel veya venöz trombozlar,fetal kayıplar,trombositopeni,nörolojik semptomlar ve serumda antifosfolipid antikor (AFA) varlığı ile karakterize sistemik otoimmün bir bozukluktur. Bu yazıda steroid,intravenöz immunglobulin ve splenektomi tedavilerine refrakter,eltrombobag tedavisine tam yanıtlı trombositopenisi olan,FV Leiden heterozigot mutant saptanan ve geçirilmiş sinüs ven trombozu olması nedeniyle ömür boyu oral antikoagulan tedavi alması gerekli primer AFS tanısı koyduğumuz genç bir erkek olgu sunulacaktır.

Keywords

Eltrombopag, Antifosfolipid antikor sendromu, Trombositopeni, Faktör V Leiden

There are 0 citations in total.

Details

Other ID	JA58SC43JJ
Journal Section	Case Report
Authors	Sinem Namdaroğlu This is me Şerife Solmaz Medeni This is me Tuğba Çetintepe This is me Ozan Barış Namdaroğlu This is me Oktay Bilgir This is me
Publication Date	April 1, 2017
Submission Date	April 1, 2017
Published in Issue	Year 2017 Volume: 10 Issue: 1

Cite

APA	Namdaroğlu, S., Medeni, Ş. S., Çetintepe, T., Namdaroğlu, O. B., et al. (2017). Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal, 10(1), 67-72.
AMA	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J. April 2017;10(1):67-72.
Chicago	Namdaroğlu, Sinem, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, and Oktay Bilgir. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10, no. 1 (April 2017): 67-72.
EndNote	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O (April 1, 2017) Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal 10 1 67–72.
IEEE	S. Namdaroğlu, Ş. S. Medeni, T. Çetintepe, O. B. Namdaroğlu, and O. Bilgir, “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”, Pam Med J, vol. 10, no. 1, pp. 67–72, 2017.
ISNAD	Namdaroğlu, Sinem et al. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10/1 (April 2017), 67-72.
JAMA	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J. 2017;10:67–72.
MLA	Namdaroğlu, Sinem et al. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal, vol. 10, no. 1, 2017, pp. 67-72.
Vancouver	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J. 2017;10(1):67-72.